Documents & Downloads

LCB-2122

Nucleoside Analogue

LCB-2122 is a nucleoside analogue that mimics adenosine and features a C2'-stereogenic all-carbon quaternary center. This compound exhibits protective effects against Doxorubicin-induced apoptosis in cardiomyocytes with an IC50 of 0.5 μM and also mitigates apoptosis induced by Imatinib. LCB-2122 activates AMPK signaling pathways, promoting the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase (ACC), while reducing mitochondrial damage linked to Doxorubicin treatment. Its biological activities make LCB-2122 a valuable reagent for investigating mechanisms related to heart failure.

Out of Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer	Adooq Bioscience
CAS Number	2210298-14-7
Applications	Nucleoside Analogue
Formula	C₁₆H₂₅ClN₅O₇P
Molecular Weight	465.83
SMILES	NC1=NC(Cl)=NC2=C1N=CN2[C@@H]3O[C@H](COP(OCC)(OCC)=O)[C@@H](O)[C@@]3(C)CO

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.